MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win

Phase 2MixedNegative

AI Analysis

Summary

MapLight Therapeutics' schizophrenia drug achieved overall Phase 2 success but failed the primary endpoint for its once-daily regimen, causing the stock to plunge over 60%.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Study overall successful but once-daily regimen missed primary endpoint

Importance:7/10

Sentiment:

-0.85

schizophreniaPhase 2clinical trialprimary endpoint missstock declineonce-daily formulation

Related Companies

$MPLT

Read the original article

Published by Endpoints News on July 27, 2026 3:17 PM

Read Original